Form 4: Labcorp EVP Vaughn Granted Stock Options, RSUs

Labcorp Holdings Inc. EVP Bryan T. Vaughn received 2,200 non-qualified stock options and 730 restricted stock units on February 10, 2026, as part of the company's incentive plan.

Summary

• Bryan T. Vaughn, EVP, Diagnostics at Labcorp Holdings Inc., was granted 2,200 non-qualified stock options on February 10, 2026.
• The stock options have an exercise price of $284.5 per share and vest in three equal annual installments starting February 10, 2027, expiring on February 9, 2036.
• Vaughn also received 730 Restricted Stock Units (RSUs) on February 10, 2026, each representing one share of common stock.
• These RSUs vest in three equal annual installments beginning February 10, 2027.
• Following these transactions, Vaughn holds an aggregate of 4,354 Restricted Stock Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with shareholder interests, without indicating any immediate operational or financial shifts.

Positives

• The grant of stock options and restricted stock units aligns management's interests with long-term shareholder value creation.
• The awards are part of the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan, indicating a structured approach to executive compensation.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the vesting and expiration schedules of the granted equity awards.

Industry Context

StockSavvy.ai notes that equity grants to executives are a standard practice across the healthcare diagnostics industry, aiming to incentivize long-term performance and retention. These grants are typical for senior leadership roles and reflect ongoing compensation strategies within the sector.

Comparison to Industry Standards

• Equity compensation packages for executives, including a mix of stock options and restricted stock units, are common across major diagnostic and laboratory services companies such as Quest Diagnostics (DGX) and Eurofins Scientific (ERF.PA).
• The structure of multi-year vesting schedules is standard, aligning executive incentives with sustained company performance over several years.
• Specific comparisons of grant sizes would require detailed analysis of peer compensation reports, but the general approach is consistent with industry benchmarks.

Stakeholder Impact

• Shareholders: The grants align executive incentives with long-term shareholder value.
• Employees: No direct impact on general employees is indicated, but it reflects the company's executive compensation strategy.

Next Steps

• The granted stock options and Restricted Stock Units will begin vesting in three equal annual installments starting February 10, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a senior executive, which is a standard component of executive compensation. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The grants align executive incentives with long-term shareholder value, which is a positive, but not a catalyst for a 'buy' or 'sell' decision based solely on this filing. Therefore, a 'hold' recommendation is appropriate as it maintains the current position without new compelling reasons to alter it.

Keywords

Labcorp Holdings Inc., LH, Bryan T. Vaughn, EVP Diagnostics, Stock Options, Restricted Stock Units, RSUs, Insider Transaction, Executive Compensation, SEC Form 4